Suppr超能文献

人类神经母细胞瘤细胞的铁代谢:铁螯合功效与DNA合成抑制之间缺乏关联。

The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.

作者信息

Richardson D R, Ponka P

机构信息

Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital.

出版信息

J Lab Clin Med. 1994 Nov;124(5):660-71.

PMID:7964124
Abstract

The mechanisms of iron uptake from transferrin and the effects of iron chelators on these processes were investigated in human neuroblastoma cells. This study was performed because numerous reports have indicated that neuroblastoma cells contain iron-rich ferritin and are also especially sensitive to iron chelation by deferoxamine. The mechanisms of iron and transferrin uptake were examined in the human neuroblastoma cell line SK-N-MC by using human transferrin labeled with iodine 125 and iron 59. Internalized and membrane-bound 59Fe and 125I-transferrin were separated with the protease pronase. Total internalized and membrane 125I-transferrin uptake was biphasic with time, whereas total and internalized 59Fe uptake was linear. Iron uptake from transferrin was prevented by incubation at 4 degrees C and also by lysosomotrophic agents. In addition, 59Fe uptake occurred by two processes. The first process was consistent with receptor-mediated endocytosis involving internalization of transferrin bound to specific binding sites. Iron uptake also occurred by a second process, which was not saturable up to a transferrin concentration of 0.06 mg/ml. In terms of quantitative iron uptake, however, the second process was far less important than receptor-mediated endocytosis. Deferoxamine (0.25 mmol/L) only slightly increased 59Fe release from prelabeled cells; the orally effective iron chelator pyridoxal isonicotinoyl hydrazone (0.25 mmol/L) was six times more effective. Moreover, when pyridoxal isonicotinoyl hydrazone (0.2 mmol/L) was added together with labeled transferrin over a 2-hour incubation, 59Fe uptake from transferrin decreased to 18% of the control value, whereas deferoxamine (0.2 mmol/L) had no appreciable effect. Even though deferoxamine (0.1 mmol/L) had little effect on 59Fe uptake or release, it reduced uptake of tritiated thymidine to 33% of the control value after a 24-hour incubation. Three analogs of pyridoxal isonicotinoyl hydrazone, pyridoxal benzoyl hydrazone (#101), pyridoxal p-methoxybenzoyl hydrazone (#107), and pyridoxal m-fluorobenzoyl hydrazone (#109), had chelation activities comparable to that of pyridoxal isonicotinoyl hydrazone and were more effective than either deferoxamine or pyridoxal isonicotinoyl hydrazone at preventing tritiated thymidine uptake. These results suggest that the pyridoxal isonicotinoyl hydrazone analogs have potential as effective antiproliferative agents and deserve further investigation.

摘要

在人神经母细胞瘤细胞中研究了从转铁蛋白摄取铁的机制以及铁螯合剂对这些过程的影响。进行这项研究是因为众多报告表明神经母细胞瘤细胞含有富含铁的铁蛋白,并且对去铁胺介导的铁螯合也特别敏感。通过使用用碘125和铁59标记的人转铁蛋白,在人神经母细胞瘤细胞系SK-N-MC中研究了铁和转铁蛋白的摄取机制。用蛋白酶链霉蛋白酶分离内化的和膜结合的59Fe和125I-转铁蛋白。总的内化和膜结合的125I-转铁蛋白摄取随时间呈双相变化,而总的和内化的59Fe摄取呈线性。在4℃孵育以及用溶酶体营养剂处理可阻止从转铁蛋白摄取铁。此外,59Fe摄取通过两个过程发生。第一个过程与受体介导的内吞作用一致,涉及与特定结合位点结合的转铁蛋白的内化。铁摄取也通过第二个过程发生,在转铁蛋白浓度高达0.06mg/ml时该过程不饱和。然而,就定量铁摄取而言,第二个过程远比受体介导的内吞作用重要性低。去铁胺(0.25mmol/L)仅略微增加预先标记细胞中59Fe的释放;口服有效的铁螯合剂吡哆醛异烟酰腙(0.25mmol/L)的效果则强6倍。此外,当在2小时孵育期间将吡哆醛异烟酰腙(0.2mmol/L)与标记的转铁蛋白一起添加时,从转铁蛋白摄取的59Fe降至对照值的18%,而去铁胺(0.2mmol/L)没有明显影响。尽管去铁胺(0.1mmol/L)对59Fe摄取或释放影响很小,但在24小时孵育后它将氚标记胸腺嘧啶核苷的摄取降低至对照值的33%。吡哆醛异烟酰腙的三种类似物,吡哆醛苯甲酰腙(#101)、吡哆醛对甲氧基苯甲酰腙(#107)和吡哆醛间氟苯甲酰腙(#109),具有与吡哆醛异烟酰腙相当的螯合活性,并且在阻止氚标记胸腺嘧啶核苷摄取方面比去铁胺或吡哆醛异烟酰腙更有效。这些结果表明吡哆醛异烟酰腙类似物有作为有效的抗增殖剂的潜力,值得进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验